NEW YORK : Novavax Inc. shares saw huge swings in extended trading as investors took a critical eye to early data on its experimental vaccine for Covid-19 following a 3,800% rally in the stock this year.The shares briefly fell as much as 34% postmarket on Tuesday, before paring the decline.
In trading before regular hours Wednesday, they were up 21%.The two-injection regimen when administered concurrently with Novavax’s immune-boosting technology generated antibody responses that were four times higher than those seen in people who had recovered from the disease.
Some of the healthy adults in the study experienced side effects including fever, headache and fatigue.Confusion over the vaccine’s safety data arose after a media report.